|
|
A telehealth tDCS approach to decrease cannabis use: Towards reducing multiple sclerosis disability in multiple sclerosis |
| 1R21DA055427-01 |
|
NIDA |
2022 |
|
|
Psychostimulants, Attention Deficit and Basal Ganglia Disorders |
| 1R21DA055980-01 |
|
NIDA |
2022 |
|
|
Dissecting functional roles of MeCP2 condensates in neurons with chemogenetic tools |
| 1R21DA056293-01 |
|
NIDA |
2022 |
|
|
Endocannabinoid-mediated neuroprotection in models of neuroAIDS in vivo |
| 5R01DA045596-05 |
|
NIDA |
2022 |
|
|
Defining the Chemical Perturbome of Neural Development and Activity |
| 1DP2NS132107-01 |
|
NINDS |
2022 |
|
|
Chemical Control of Misfolded Protein Fate |
| 1DP2NS132610-01 |
|
NINDS |
2022 |
|
|
Parkinsons disease therapies targeting GUCY2C |
| 1F30NS125921-01A1 |
|
NINDS |
2022 |
|
|
Pathogenic mechanism of intrathecally synthesized immunoglobulins in a mouse model of progressive multiple sclerosis |
| 1F31NS118955-01A1 |
|
NINDS |
2022 |
|
|
Neural Mechanisms Supporting Implicit and Explicit Sensorimotor Learning |
| 1F31NS120448-01A1 |
|
NINDS |
2022 |
|
|
Engineered extracellular vesicles as a targeted drug delivery system for multiple sclerosis |
| 1F31NS120590-01A1 |
|
NINDS |
2022 |
